Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Large-scale production of human iPSC-derived macrophages for drug screening

ABSTRACT: Large-scale production of human iPSC-derived macrophages for drug screening

PROVIDER: PRJNA628531 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11612939_1.fastq.gz	Fastqsanger.gz
	SRR11612939_2.fastq.gz	Fastqsanger.gz
	SRR11612940_1.fastq.gz	Fastqsanger.gz
	SRR11612940_2.fastq.gz	Fastqsanger.gz
	SRR11612941_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 100

Similar Datasets

Large-scale production of human iPSC-derived macrophages for drug screening

Project description:Tissue resident macrophages are key players in inflammatory processes and their activation and functionality is crucial in health and disease. Diseases associated with alterations in homeostasis or dysregulation of the innate immune system are numerous and include allergic reactions, autoimmune diseases as well as cancer. Hence, these cells are of high interest in drug development. Currently, the main sources of macrophages used in drug development are still primary cells isolated from blood or tissue, or immortalized cell lines (e.g. THP-1). Here, we describe an improved method for large-scale production of tissue resident macrophages from induced pluripotent stem cells (iPSC) in unprecedented yields. For this, iPSC-derived macrophages are thoroughly characterized to confirm their cell identity and thus their suitability for screening purposes. We demonstrate that this method to generate macrophages from iPSC overcomes the limitations of using primary cells, i.e. donor variability and limited availability of large cell numbers. Notably, the cells recapitulate key functional characteristics, including cytokine release, phagocytosis and migration. Genetic modifications can be introduced at the macrophage progenitor stage, so this methodology will facilitate the generation of reporters and gain- and loss-of-function mutants in an isogenetic background, essential assets for target validation.

2020-07-07 | GSE149377 | GEO

Large-scale, genome-wide iPSC chromatin co-accessibility analysis

Project description:Large-scale, genome-wide iPSC chromatin co-accessibility analysis

| PRJNA839707 | ENA

Large-Scale Production of Human iPSC-Derived Macrophages for Drug Screening.

Project description:Tissue-resident macrophages are key players in inflammatory processes, and their activation and functionality are crucial in health and disease. Numerous diseases are associated with alterations in homeostasis or dysregulation of the innate immune system, including allergic reactions, autoimmune diseases, and cancer. Macrophages are a prime target for drug discovery due to their major regulatory role in health and disease. Currently, the main sources of macrophages used for therapeutic compound screening are primary cells isolated from blood or tissue or immortalized or neoplastic cell lines (e.g., THP-1). Here, we describe an improved method to employ induced pluripotent stem cells (iPSCs) for the high-yield, large-scale production of cells resembling tissue-resident macrophages. For this, iPSC-derived macrophage-like cells are thoroughly characterized to confirm their cell identity and thus their suitability for drug screening purposes. These iPSC-derived macrophages show strong cellular identity with primary macrophages and recapitulate key functional characteristics, including cytokine release, phagocytosis, and chemotaxis. Furthermore, we demonstrate that genetic modifications can be readily introduced at the macrophage-like progenitor stage in order to interrogate drug target-relevant pathways. In summary, this novel method overcomes previous shortcomings with primary and leukemic cells and facilitates large-scale production of genetically modified iPSC-derived macrophages for drug screening applications.

| S-EPMC7370446 | biostudies-literature

PHDs-seq: A Large-scale Phenotypic Screening Method for Drug Discovery through Parallel Multi-readout Quantification

Project description:PHDs-seq: A Large-scale Phenotypic Screening Method for Drug Discovery through Parallel Multi-readout Quantification

| PRJNA944937 | ENA

Large-scale microRNA high-throughput screening identifies miR-515-3p and miR-519e-3p as inducers of human iPSC-cardiomyocyte proliferation

Project description:Large-scale microRNA high-throughput screening identifies miR-515-3p and miR-519e-3p as inducers of human iPSC-cardiomyocyte proliferation

| PRJEB44561 | ENA

NHGRI Large Scale Sequencing Program

Project description:NHGRI Large Scale Sequencing Program

| PRJNA158497 | ENA

Large-Scale CLL Genome Analysis

Project description:Large-Scale CLL Genome Analysis

| PRJNA80303 | ENA

Large-scale swine wastewater

Project description:Large-scale swine wastewater Raw sequence reads

| PRJNA1152766 | ENA

Purification of Human iPSC-derived Cardiomyocytes in a Large Scale Using MicroRNA Switch and Magnetic-activated Cell Sorting

Project description:We showed novel synthetic microRNA (miRNA) switch system, which can purify large quantities of iPSC-CMs using magnetic-activated cell sorting (MACS). We used miR-208a, which is specifically expressed in cardiomyocytes, as a specific miRNA of CMs, and CD4 as a selection marker for MACS. We synthesized a miRNA switch encoding CD4 tagged with complementary sequences against miR-208a (miR-208a CD4 switch). We transfected this switch into differentiated cells, and easily got efficiently purified CMs in a large scale with MACS. In addition, we demonstrated that purified cells were shown to be engrafted as CMs in mouse hearts.

2022-05-30 | GSE153714 | GEO

Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection

Project description:Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action These data support the publication titled "Development of a Large-Scale Chemogenomics Database to Improve Drug Candidate Selection and to Understand Mechanisms of Chemical Toxicity and Action" Copyright (c) 2005 by Iconix Pharmaceuticals, Inc. Guidelines for commercial use: http://www.iconixbiosciences.com/guidelineCommUse.pdf Keywords: other

2005-05-31 | E-GEOD-2409 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data